The conditions most commonly associated with unexplained hypercobalaminemia include: Liver disease
(1993) Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans
A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
Knowing their treatment helps patients manage their condition and stay healthy
Many patients have normal IGF-1 levels yet exhibit clear clinical signs of functional GH deficiency
The compound has attracted significant interest in preclinical research for its effects on adipocyte metabolism, body composition, and muscle function in animal models